Cypher clarification
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis' Cypher drug-eluting coronary stent uses sirolimus (Rapamune), licensed from Wyeth and bound to the stent using SurModics' coating technology and related reagents. "The Gray Sheet" had incorrectly stated that the Cypher uses paclitaxel (1"The Gray Sheet" Jan. 6, 2003, p. 3)...
You may also be interested in...
Guidant Shifts To Everolimus As Stents Developed With Cook Under-Achieve
Guidant will pursue development of two polymer-coated everolimus-eluting stent platforms in the wake of disappointing study results with its Achieve non-polymer paclitaxel-eluting stent
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.